# GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer

Source: https://onco.cc/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/  
OnCo record `paper-garnet-dostarlimab-oaknin-jama-oncol-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The PD-1 antibody dostarlimab shrank tumours in about four in ten women with mismatch repair-deficient endometrial cancer that had progressed after platinum chemotherapy, with most responses still ongoing after a year.

## Summary

Interim analysis of the phase 1 GARNET trial's cohort of 104 patients with mismatch repair-deficient recurrent or advanced endometrial cancer treated with dostarlimab after platinum-based therapy.

Objective response was 42.3 percent with complete response in 12.7 percent, and 93 percent of responses were ongoing at data cut-off; immune-related toxicity was manageable.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: JAMA Oncology
- Year: 2020
- DOI: 10.1001/jamaoncol.2020.4515
- Authors: Oaknin A, Tinker AV, Gilbert L, et al.
- Findings: Objective response 42.3 percent; complete response 12.7 percent.; Median duration of response not reached; 93 percent of responses ongoing.
- What it means: Dostarlimab was approved for previously treated mismatch repair-deficient endometrial cancer on these data, before moving into first-line combination in RUBY.
- Caveats: Single-arm, interim data.; Response in mismatch repair-proficient disease was much lower (about 13 percent) in a parallel cohort.

## Sources

- JAMA Oncol 2020: https://doi.org/10.1001/jamaoncol.2020.4515
- PubMed: https://pubmed.ncbi.nlm.nih.gov/33001143/

## Connected records

- cancers: [Mismatch-repair-deficient endometrial cancer](https://onco.cc/cancers/endometrial-mmr-deficient/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- trials: [GARNET](https://onco.cc/trials/garnet/)
- journals: [JAMA Oncology](https://onco.cc/journals/jama-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-garnet-dostarlimab-oaknin-jama-oncol-2020.json